Trial Profile
An Open Label, Randomized, Multiple-Dose, Parallel Study To Evaluate The Safety And Efficacy Of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension (Intas Pharmaceuticals Ltd.) And Taxotere (Docetaxel Injection Concentrate, Aventis Pharma Ltd.) in Locally Advanced or Metastatic Breast Cancer Patients after failure of prior chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 05 Dec 2018 Status changed from recruiting to completed.
- 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 15 Dec 2010 Status changed from not yet recruiting to recruiting Clinical Trials Registry - India.